Phospholipidosis in healthy subjects participating in clinical studies
METADATA ONLY
Loading...
Author / Producer
Date
2010-09
Publication Type
Journal Article
ETH Bibliography
no
Citations
Altmetric
METADATA ONLY
Data
Rights / License
Abstract
Lipid storage disorders and phospholipidosis share similar morphologic characteristics displayed as lamellar bodies at ultrastructural level. More than 50 cationic amphiphilic drugs (CADs), including antidepressants, antianginal, antimalarial, and cholesterol-lowering agents, have been reported to induce phospholipidosis, however, the mechanism by which this occurs has not been extensively studied and is not well understood. Both the Food and Drug Administration (FDA) and the pharmaceutical industry recognized drug-induced phospholipidosis as a significant challenge for drug development. In a randomized, double-blind, placebo-controlled, active-controlled, ascending multiple-dose study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a new investigational drug (an antihypertensive drug in early drug development) in healthy male subjects, possible drug-induced phospholipidosis was also explored ultrastructurally. Given the presence of these structures both pretreatment and following placebo treatment, it was concluded that the presence of phospholipid-like structures in individual volunteers could be a normal background finding in neutrophilic granulocytes thus emphasizing their role as natural phagocytic cells. Recommendations for the conduct of this type of studies are given.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
62 (5)
Pages / Article No.
567 - 571
Publisher
Elsevier
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Phospholipdiosis; Drug-induced; Healthy volunteers; Phospholipid-like structures; Neutrophilic granulocytes; Monocytes; Electron microscopy
Organisational unit
02803 - Collegium Helveticum / Collegium Helveticum